Trending: Eli Lilly Reports Strong Sales of Weight-Loss, Diabetes Drugs
Provided by
Dow Jones
14:20 -- Eli Lilly & Co. is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The company reported first-quarter financial results and said demand for its weight-loss drugs, including Zepbound, and for diabetes-drug Mounjaro were strong. The company plans to expand manufacturing capacity to meet demand, The Wall Street Journal reported. Dow Jones & Co. owns Factiva. (stephen.nakrosis@wsj.com)
(END) Dow Jones Newswires
April 30, 2024 14:35 ET (18:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing